Partnership Expansion: OptimizeRx has signed an exclusive multi-year agreement with a high-demand e-prescribing platform, significantly enhancing its in-workflow point-of-care network and fortifying its competitive position in the market.
NPI Reach Increase: The addition of new partners boosts OptimizeRx's National Provider Identifier (NPI) reach by 37%, enabling clients to engage healthcare providers more effectively within clinical workflows.
Renewal Strengthening: The company has renewed multi-year agreements with two top-performing electronic health record (EHR) and eRx platforms, one of which establishes an exclusive partnership, ensuring visibility into future channel revenue.
Strategic Positioning: CEO Steve Silvestro stated that by deepening relationships with high-value partners, OptimizeRx is laying the groundwork for sustained profitable growth, addressing life sciences manufacturers' demand for in-workflow engagement.
OPRX
$12.77+Infinity%1D
Analyst Views on OPRX
Wall Street analysts forecast OPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPRX is 24.97 USD with a low forecast of 17.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast OPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPRX is 24.97 USD with a low forecast of 17.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 13.180
Low
17.00
Averages
24.97
High
32.00
Current: 13.180
Low
17.00
Averages
24.97
High
32.00
Stephens
Jeff Garro
Equal Weight
downgrade
$20 -> $17
2025-11-17
Reason
Stephens
Jeff Garro
Price Target
$20 -> $17
2025-11-17
downgrade
Equal Weight
Reason
Stephens analyst Jeff Garro lowered the firm's price target on OptimizeRx to $17 from $20 and keeps an Equal Weight rating on the shares. Noting that shares are up greater than 200% year-to-date, the firm views the current risk/reward as balanced and looks to confirm business momentum exceeding conservative pipeline assumptions.
B. Riley
Buy
upgrade
$18 -> $28
2025-11-07
Reason
B. Riley
Price Target
$18 -> $28
2025-11-07
upgrade
Buy
Reason
B. Riley raised the firm's price target on OptimizeRx to $28 from $18 and keeps a Buy rating on the shares. The firm views the company's Q3 report as strong.
Lake Street
Buy
maintain
$20 -> $24
2025-11-07
Reason
Lake Street
Price Target
$20 -> $24
2025-11-07
maintain
Buy
Reason
Lake Street raised the firm's price target on OptimizeRx to $24 from $20 and keeps a Buy rating on the shares, telling investors that the firm was "pleased" with the company's third consecutive strong quarter and guide. The FY26 revenue midpoint equates to growth of 13%, which compares favorably to the 11% consensus, the analyst noted.
Roth Capital
Buy
upgrade
$27 -> $32
2025-11-07
Reason
Roth Capital
Price Target
$27 -> $32
2025-11-07
upgrade
Buy
Reason
Roth Capital raised the firm's price target on OptimizeRx to $32 from $27 and keeps a Buy rating on the shares. The company reported strong Q3 results and beat its guidance again, while its visibility is clearly much improved after 2024's weak execution, the analyst tells investors in a research note.
About OPRX
OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
